Linked Life Data

6107932

Source:http://linkedlifedata.com/resource/pubmed/id/6107932

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1981-1-29
pubmed:abstractText
A double-blind, placebo-controlled trial was carried out in 32 male patients to assess the effect of naftidrofuryl (40 mg i.m. 3-times for 6 days) on their serum gamma-glutamyl transpeptidase (GGT) levels. This enzyme is one of the hepatic microsomal enzymes and is now considered to be a reliable biochemical marker of enzyme induction. Measurements of serum GGT before and after treatment showed that there was no significant difference in levels between the two groups of patients. The results showed that naftidrofuryl did not increase serum GGT levels, in fact the mean post-treatment levels (36.06 +/- 10.63 I.U./l) were found to be lower than those before treatment (60.59 +/- 28.37 I.U./l). It is concluded, therefore, that naftidrofuryl may not induce hepatic microsomal enzymes and that interference with rates of metabolism, via enzyme induction, of other drugs used concurrently need not be anticipated.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0308-051X
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
305-8
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1980
pubmed:articleTitle
The effect of naftidrofuryl ('Praxilene') on hepatic microsomal enzymes.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial